OIG Greenlights Digital Health Program Offering Free Smartphones to Patients

04 February 2019 Health Care Law Today Blog
Author(s): Nathaniel M. Lacktman

Last week, the federal HHS Office of Inspector General (OIG) gave the greenlight to allow a virtual care company and pharmaceutical manufacturer to loan patients free smartphones, so the patients (which include Medicare beneficiaries) could use the smartphones to track their drug therapy adherence via a mobile digital health app. The OIG’s recent Advisory Opinion marks the sixth favorable telemedicine/digital health advisory opinion issued by OIG to date. This article describes the drug and digital health technology, outlines the proposed program for free smartphones, and explains why OIG issued a favorable advisory opinion.

The Digital Health Therapeutic Technology

The company requesting the advisory opinion is an affiliate of a global pharmaceutical manufacturer which developed a drug used as an adjunctive treatment for a specific disorder (note: OIG redacted the drug’s identifying information). According to the company, medication nonadherence is a problem in this specific patient population due to factors associated with the disorder itself.  The company provided clinical research articles demonstrating that medication nonadherence for these patients results in higher utilization of health care services and increased costs.

In addition, the FDA recently approved a digital therapeutics version of the drug, which consists of a tablet of the drug embedded with an ingestible sensor (an ingestion event marker or IEM).  When a patient ingests the drug, the IEM gives off a mild electrophysiological signal that is detected by a wearable sensor (a patch) on the patient’s abdomen. The patch records when the patient ingests the drug and records certain physiologic indicators of the patient’s rest patterns and activity. A third element of the digital health therapy is a smartphone app, which uses Bluetooth to wirelessly collect the information generated via the patch.

The app also allows patients to self-report information such as how well they rested and their current mood. All the information collected in the app is transmitted to a secure cloud-based server where the patient’s health care providers can remotely monitor and access that information through web-based portals.

The Proposed Arrangement

Under the arrangement, the company wanted to loan free smartphones to patients, including Medicare beneficiaries, who have been prescribed the drug. This way, the patients could enjoy the full functionality of the digital health therapy, even if they do not own a smartphone.

There were some important limitations on the program. The company would only loan the free smartphones to patients who: (1) have been prescribed the drug; (2) meet any applicable approval or other insurer requirements; (3) have an income level below a certain percentage of the Federal poverty level; (4) do not already own a device capable of supporting and using the app; and (5) are United States citizens.

The smartphones (refurbished iPhones or Android devices) have limited functionality and can only be used to operate the preloaded app and make domestic telephone calls. At the end of the 8-12 week drug therapy regimen, the company will retrieve the smartphone from the patient (or remotely disable it if not returned). The program will not be advertised directly to patients.  Instead, the company will educate prescribing doctors about the program, explaining how doctors could screen potential patient-applicants and enroll them in the program on behalf of their patients.

The Promotes Access to Care Exception

Even though the smartphone is locked, it remains something of value to patients because it can make domestic phone calls. Thus, it constitutes remuneration under both the Civil Monetary Penalties Law and the Anti-Kickback Statute. Yet, OIG concluded the arrangement satisfied the Promotes Access to Care Exception to “remuneration” under Social Security Act § 1128A(i)(6)(F) and 42 C.F.R. § 1003.110 (“Incentives given to individuals to promote the delivery of preventive care services where the delivery of such services is not tied (directly or indirectly) to the provision of other services reimbursed in whole or in part by Medicare or an applicable State health care program.”)

The OIG concluded the program satisfied the Access to Care Exception for the following five main reasons:

  • The smartphone app was essential to the patient accessing the full scope of benefits of the digital health therapy, and loaning a smartphone to make that possible would improve patients’ ability to benefit from the drug.
  • The program was unlikely to interfere with clinical decision making because only certain patients who met specific conditions (e.g., financial need, no pre-existing device) would be eligible for the free smartphone. Moreover, a doctor would likely prescribe the digital therapy drug based on its ability to transmit data via RPM technologies, not based on the fact the doctor’s patient could get a free smartphone for 8-12 weeks.
  • The free smartphone itself would not likely lead to increased utilization or costs to Federal health care programs.
  • The fact that the program would not be directly advertised to patients was an important safeguard against improper beneficiary influence or inducements.
  • The limited smartphone functionality and 12-week duration were favorable elements, and OIG notably stated if the phone offered additional functionality (e.g., internet access), they might have reached a different conclusion on the proposed arrangement.

What it Means for Telemedicine & Digital Health Companies

OIG included its traditional disclaimer that the advisory opinion can only be relied upon by the specific company that requested it, and the opinion would be null if any material facts were not disclosed.  Companies offering similar digital health therapeutics or remote patient monitoring programs should closely review the opinion because it offers insight into the government’s view on how technology can promote access to care. Companies evaluating or developing similar programs offering free or discounted technology should carefully consider the safeguards enumerated in OIG’s analysis prior to launch.

Want to learn more?

Join us on February 13, 2019 for “Digital Health and the FDA: Top 5 Legal Issues to Understand.” Members of the American Telemedicine Association’s Business & Finance Group can attend the presentation via the membership portal.  Click here for more info.

For more information on telemedicine, telehealth, virtual care, remote patient monitoring, digital health, and other health innovations, including the team, publications, and representative experience, visit Foley’s Telemedicine & Digital Health Industry Team.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.